个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Zhang Yifei[1] * ; Liu Ruixin[1] * ; Chen Yufei[1] * ; Cao Zhiwen[1] * ; Liu Cong[1] * ; Bao Riqiang[1] ; Wang Yufan[2] ; Huang Shan[3] ; Pan Shijia[4] ; Qin Li[5] ; Wang Jiqiu[1] ; Ning Guang[1] ; Wang Weiqing[1] ;
机构： [1]Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. [2]Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China. [3]Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China. [4]Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China. [5]Department of Endocrinology, Chongming hospital affiliated to Shanghai University of Health & Medicine Sciences, Shanghai 202150, China.
出处：
DOI： 10.1016/j.cmet.2024.12.010
ISSN：

摘要：
Akkermansia muciniphila is a promising target for managing obesity and type 2 diabetes (T2D), but human studies are limited. We conducted a 12-week randomized, double-blind, placebo-controlled trial involving 58 participants with overweight or obese T2D, who received A. muciniphila (AKK-WST01) or placebo, along with routine lifestyle guidance. Both groups showed decreases in body weight and glycated hemoglobin (HbA1c), without significant between-group differences. In participants with low baseline A. muciniphila, AKK-WST01 supplementation showed high colonization efficiency and significant reductions in body weight, fat mass, and HbA1c, which were not found in the placebo group. However, AKK-WST01 supplementation showed poor colonization and no significant clinical improvements in participants with high baseline A. muciniphila. These findings were verified in germ-free mice receiving feces with low or high A. muciniphila. Our study indicates that metabolic benefits of A. muciniphila supplementation could depend on its baseline intestinal levels, supporting the potential for gut microbiota-guided probiotic supplementation. (ClinicalTrials.gov number, NCT04797442).Copyright © 2024. Published by Elsevier Inc.

基金：
National Key Research and DevelopmentProgram of China (2021YFA1301 103 and 2022YFC2505201), National NaturalScience Foundation of China (82088102, 92157204, 92357305, 81930021,82250901, 82270896, 82470898, and 82200939), Science and TechnologyComission of Shanghal Munlclpallty (23XD1422400 and 21JC1404400)，innovative research team of high-level local universities in Shanghai, andThe Leader Project of the Oriental Talent Program in 2022 (mo. 153).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 生物学
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
最新[2025]版：
大类 | 1 区 生物学
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
JCR分区：
出版当年[2023]版：
Q1 CELL BIOLOGY Q1 ENDOCRINOLOGY & METABOLISM
最新[2023]版：
Q1 CELL BIOLOGY Q1 ENDOCRINOLOGY & METABOLISM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Yifei,Liu Ruixin,Chen Yufei,et al.Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut[J].Cell Metabolism.2025,37(3):doi:10.1016/j.cmet.2024.12.010.
APA：
Zhang Yifei,Liu Ruixin,Chen Yufei,Cao Zhiwen,Liu Cong...&Wang Weiqing.(2025).Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut.Cell Metabolism,37,(3)
MLA：
Zhang Yifei,et al."Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut".Cell Metabolism 37..3(2025)

资源点击量：23581 今日访问量：2 总访问量：1284 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)